Advanced Search

Technical Analysis for SGTX - Sigilon Therapeutics, Inc.

Grade Last Price % Change Price Change
F 18.7938 7.82% 1.36
SGTX closed down 1.86 percent on Monday, April 12, 2021, on 33 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical SGTX trend table...
Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 7.82%
New 52 Week Low Weakness 7.82%
Wide Bands Range Expansion 7.82%
Down 3 Days in a Row Weakness 7.82%
Down 4 Days in a Row Weakness 7.82%
Down 5 Days in a Row Weakness 7.82%
Oversold Stochastic Weakness 7.82%
New 52 Week Closing Low Bearish 5.82%
New 52 Week Low Weakness 5.82%
Wide Bands Range Expansion 5.82%
Older End-of-Day Signals for SGTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 1 hour ago
60 Minute Opening Range Breakout about 4 hours ago
Rose Above Previous Day's High about 4 hours ago
Up 3% about 4 hours ago
Up 2% about 4 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

  • Earnings date: ???
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Disease Diabetes Health Sciences Hemophilia Chronic Disease Chronic Diseases Hemophilia A Mucopolysaccharidosis Haemophilia Mucopolysaccharidosis Type

Is SGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 8 Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Mar 30 Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
Mar 26 The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Mar 18 Sigilon Therapeutics EPS misses by $0.59, beats on revenue
Mar 18 Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Mar 8 Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6%
Mar 5 Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
Mar 5 Sigilon Therapeutics' SIG-007 an Orphan Drug in U.S. for Fabry disease
Mar 5 Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
Mar 4 Sigilon Therapeutics to Present at Barclays Global Healthcare Conference
See more SGTX news...

Indicators

Indicator Value
52 Week High 54.32
52 Week Low 16.55
Average Volume 141,634
200-Day Moving Average 0.00
50-Day Moving Average 27.48
20-Day Moving Average 20.89
10-Day Moving Average 19.30
Average True Range 2.59
ADX 31.42
+DI 11.31
-DI 25.91
Chandelier Exit (Long, 3 ATRs ) 22.58
Chandelier Exit (Short, 3 ATRs ) 24.32
Upper Bollinger Band 25.94
Lower Bollinger Band 15.83
Percent B (%b) 0.16
BandWidth 48.42
MACD Line -2.66
MACD Signal Line -2.67
MACD Histogram 0.008
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.57
Resistance 3 (R3) 19.51 18.74 19.21
Resistance 2 (R2) 18.74 18.20 18.77 19.09
Resistance 1 (R1) 18.09 17.86 17.70 18.14 18.97
Pivot Point 17.32 17.32 17.13 17.35 17.32
Support 1 (S1) 16.66 16.77 16.28 16.72 15.89
Support 2 (S2) 15.89 16.44 15.92 15.77
Support 3 (S3) 15.24 15.89 15.65
Support 4 (S4) 15.29